Trial Profile
Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Hypoplastic left heart syndrome
- Focus Adverse reactions
- Acronyms ELPIS; ELPIS I
- Sponsors Longeveron
- 08 Apr 2024 According to Longeveron media release, company anticipate completion of the 5-year follow-up from this Phase 1 HLHS study by the second half of 2024 which, if we continue to have similar results, may allow us to announce additional favorable results on continued transplant-free survival.
- 13 Nov 2023 Results assessing long-term transplant-free survival, presented at the American Heart Association Scientific Sessions 2023.
- 02 Oct 2023 Planned primary completion date changed from 1 Feb 2021 to 30 Jun 2024.